open access

Vol 19, No 2 (2016)
Original articles
Published online: 2016-07-29
Submitted: 2016-07-23
Accepted: 2016-07-27
Get Citation

Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC

Vera Artiko, Aida Afgan, Jelena Petrović, Branislava Radović, Nebojša Petrović, Marina Vlajković, Dragana Šobić-Šaranović, Vladimir Obradović
DOI: 10.5603/NMR.2016.0020
·
Pubmed: 27479786
·
Nucl. Med. Rev 2016;19(2):99-103.

open access

Vol 19, No 2 (2016)
Original articles
Published online: 2016-07-29
Submitted: 2016-07-23
Accepted: 2016-07-27

Abstract

BACKGROUND: This paper is the short review of our preliminary results obtained with 99mTc-EDDA/HYNIC-TOC.

MATERIAL AND METHODS: The total of 495 patients with different neuroendocrine tumors were investigated during last few years.

RESULTS: There have been 334 true positive (TP), 73 true negative (TN), 6 false positive (FP) and 82 false negative findings (FN). Diagnosis was made according to SPECT findings in 122 patients (25%). The mean T/NT ratio for TP cases was significantly higher (p < 0.01) on SPECT (3.12 ± 1.13) than on whole body scan (2.2 ± 0.75). According to our results, overall sensitivity of the method is 80%, specificity 92%, positive predictive value 98%, negative predictive value 47% and accuracy 82%. Fifteen TP patients underwent therapy with 90Y-DOTATATE.

CONCLUSION: Scintigraphy of neuroendocrine tumors with 99mTc-Tektrotyd is a useful method for diagnosis, staging and follow up of the patients suspected to have neuroendocrine tumors. SPECT had important role in diagnosis. It is also helpful in the appropriate choice of the therapy, including the peptide receptor radionuclide therapy. In the absence of 68Ga-labeled peptides and PET/CT, the special emphasize should be given to application of SPECT/CT as well as to the radioguided surgery.

Abstract

BACKGROUND: This paper is the short review of our preliminary results obtained with 99mTc-EDDA/HYNIC-TOC.

MATERIAL AND METHODS: The total of 495 patients with different neuroendocrine tumors were investigated during last few years.

RESULTS: There have been 334 true positive (TP), 73 true negative (TN), 6 false positive (FP) and 82 false negative findings (FN). Diagnosis was made according to SPECT findings in 122 patients (25%). The mean T/NT ratio for TP cases was significantly higher (p < 0.01) on SPECT (3.12 ± 1.13) than on whole body scan (2.2 ± 0.75). According to our results, overall sensitivity of the method is 80%, specificity 92%, positive predictive value 98%, negative predictive value 47% and accuracy 82%. Fifteen TP patients underwent therapy with 90Y-DOTATATE.

CONCLUSION: Scintigraphy of neuroendocrine tumors with 99mTc-Tektrotyd is a useful method for diagnosis, staging and follow up of the patients suspected to have neuroendocrine tumors. SPECT had important role in diagnosis. It is also helpful in the appropriate choice of the therapy, including the peptide receptor radionuclide therapy. In the absence of 68Ga-labeled peptides and PET/CT, the special emphasize should be given to application of SPECT/CT as well as to the radioguided surgery.

Get Citation

Keywords

scintigraphy, 99mTc-EDDA/HYNIC-TOC, NET, SPECT

About this article
Title

Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC

Journal

Nuclear Medicine Review

Issue

Vol 19, No 2 (2016)

Pages

99-103

Published online

2016-07-29

DOI

10.5603/NMR.2016.0020

Pubmed

27479786

Bibliographic record

Nucl. Med. Rev 2016;19(2):99-103.

Keywords

scintigraphy
99mTc-EDDA/HYNIC-TOC
NET
SPECT

Authors

Vera Artiko
Aida Afgan
Jelena Petrović
Branislava Radović
Nebojša Petrović
Marina Vlajković
Dragana Šobić-Šaranović
Vladimir Obradović

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl